CCM
SUPN icon

Consonance Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Consonance Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,566,923
Closed -$43.1M – 30
2015
Q1 		$43.1M Buy
+3,566,923
New +$33.7M 3.93% 12
2014
Q3 		– Sell
-1,440,008
Closed -$15.8M – 29
2014
Q2 		$15.8M Buy
+1,440,008
New +$12.8M 2.35% 18

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Consonance Capital Management's SUPN Position: Q2 2015 in Review

Consonance Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 3,566,923 shares — an estimated $43.1M sold.

Consonance Capital Management first reported a position in SUPN in Q2 2014 and held it in 2 quarters. The position peaked at $43.1M in Q1 2015. 166 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Consonance Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Consonance Capital Management sold 3,566,923 Supernus Pharmaceuticals shares in Q2 2015, an estimated $43.1M.
  • Consonance Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Consonance Capital Management's Supernus Pharmaceuticals position peaked at $43.1M in Q1 2015.
  • 166 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Consonance Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.